呼吸系统疾病（包括病毒感染、肺癌、慢性阻塞性肺疾病及肺纤维化等）严重威胁人民生命健康，也是创新药物研发的重要方向。近年来，结构生物学、化学生物学、人工智能辅助药物设计（AI）及自动化高通量筛选等技术的快速发展，为原创药物发现和作用机制研究提供了新的机遇。本课题组围绕呼吸系统疾病创新药物研发，重点关注以下研究方向：

1. 靶向抗病毒与抗肿瘤等呼吸系统疾病创新药物研发及作用机制研究

2. 呼吸系统疾病相关药物靶标（激素核受体、G蛋白偶联受体等）的结构与功能研究

3. 基于呼吸系统疾病药物靶标的活性化合物发现及高通量药物筛选（HTS）技术研究

课题组网站： https://shanglab.org/

1、国家自然科学基金面上项目（主持，课题编号：82170473）

2、广州国家实验室专项（主持，GZNL2024A03003，2023-2028）

1、Wu Q, Lin Y, Chen J, et al., Li W, Huang W, Tang M, Shang J*. (2026). A Miniaturized, Automated Proteomic Sample Preparation Platform for High-Throughput Target Deconvolution of Natural Products. Analytical Chemistry, 2026, 98, 15676−15688

2、Zhong Z#, Liu H#, Wu Q#, Cao B#, Peng Y, Liu M, et al., Shang J*, Zou T*. (2026). Beyond Thiol-Enzyme Inhibition: Sterically Bulky NHC-Au(I) Complexes are Catalytically Active Anticancer Agents with Reprogrammed Immunomodulatory Function. J. Am. Chem. Soc., 2026, 148, 8511-8523

3、Qiu X, Li W, Li X, Wu B, et al., Wu K, Lu Y, Tang M, Lin H, Shang J*. (2025). Discovery of Fluorescent Probe ABDS-2 for Farnesoid X Receptor Modulator Characterization and Cell-Based Imaging. Analytical Chemistry, 2025, 97, 4, 2019–2027

4、Lu Y, Yang Q, Ran T, Zhang G, et al., Chen H*, Chen X*, Shang J*. (2024). Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19. Nature Communications, (2024) 15(1), 10169.

5、Shang J*, Kojetin DJ*. (2024). Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPARγ. eLife,13: RP99782.

6、Yang Q, Xue B, Liu F, Lu Y, Tang J, et al., Shang J*, Chen X*. (2024). Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein. Signal Transduction and Targeted Therapy, 9(1):144

7、Shang J, Kojetin DJ. (2021). Structural Mechanism Underlying Ligand Binding and Activation of PPARγ. Cell: Structure, 29(9), 940-950.

8、Shang J, Mosure SA, Zheng J, Brust R, Bass J, Nichols A, Solt LA, Griffin PR and Kojetin DJ. (2020). A Molecular Switch Regulating Transcriptional Repression and Activation of PPARγ. Nature Communications, 11(1), 956.

9、Shang J, Brust R, Griffin PR, Kamenecka TM and Kojetin DJ. (2019). Quantitative Structural Assessment of Graded Receptor Agonism. (PNAS) Proceedings of the National Academy of Sciences, 116 (44) 22179-22188

10、Shang J, Brust R, Mosure SA, Bass J, Munoz-Tello P, Lin H, Hughes TS, Tang M, Ge Q, Kamenekca TM and Kojetin DJ. (2018). Cooperative Cobinding of Synthetic and Natural Ligands to the Nuclear Receptor PPARγ. eLife, 7, e43320.